Literature DB >> 16873435

Correlation between tumor response to first-line chemotherapy and prognosis in advanced gastric cancer patients.

W Ichikawa1, Y Sasaki.   

Abstract

BACKGROUND: In advanced gastric cancer, the relationship between tumor response and prognosis is far from clear.
METHODS: We performed a pooled analysis on published data from 4593 patients in 25 randomized trials of first-line chemotherapy for advanced gastric cancer. A weighed analysis was used to investigate the correlation between objective response rate (RR) and time to progression (TTP) and overall survival time (OS).
RESULTS: A moderate correlation was found between RR and TTP and OS (r = 0.49 and r = 0.45, respectively) in all 25 trials. In treatment arms without new drugs including irinotecan, taxanes, or oxaliplatin, RR also was associated with TTP and OS (r = 0.56 and r = 0.47, respectively). However, no association between RR and OS was found, whereas there was a moderate correlation between RR and TTP (r = 0.41) in treatment arms using new drugs.
CONCLUSIONS: Our results indicated that response to treatment was related to TTP and OS. The potential role of objective response as a surrogate in chemotherapy trials of advanced gastric cancer warrants further investigation, especially with regard to treatment with new drugs.

Entities:  

Mesh:

Year:  2006        PMID: 16873435     DOI: 10.1093/annonc/mdl174

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  12 in total

1.  Bax predicts outcome in gastric cancer patients treated with 5-fluorouracil, leucovorin, and oxaliplatin palliative chemotherapy.

Authors:  Seong Hyun Jeong; Jae Ho Han; Jang Hee Kim; Mi Sun Ahn; Yoon Ho Hwang; Hyun Woo Lee; Seok Yun Kang; Joon Seong Park; Jin-Hyuk Choi; Kwang Jae Lee; Seung Soo Sheen; Ho-Yeong Lim
Journal:  Dig Dis Sci       Date:  2010-05-26       Impact factor: 3.199

2.  Progression-free survival in first-line chemotherapy is a prognostic factor in second-line chemotherapy in patients with advanced gastric cancer.

Authors:  Kenji Hashimoto; Atsuo Takashima; Kengo Nagashima; Shun-suke Okazaki; Takako Eguchi Nakajima; Ken Kato; Tetsuya Hamaguchi; Yasuhide Yamada; Yasuhiro Shimada
Journal:  J Cancer Res Clin Oncol       Date:  2010-07       Impact factor: 4.553

3.  Bax expression is predictive of favorable clinical outcome in chemonaive advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen.

Authors:  Filippo Pietrantonio; Pamela Biondani; Filippo de Braud; Alessandro Pellegrinelli; Giampaolo Bianchini; Federica Perrone; Barbara Formisano; Maria Di Bartolomeo
Journal:  Transl Oncol       Date:  2012-06-01       Impact factor: 4.243

4.  Sex and gender disparities in patients with advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry.

Authors:  J Gallego Plazas; A Arias-Martinez; A Lecumberri; E Martínez de Castro; A Custodio; J M Cano; R Hernandez; A F Montes; I Macias; A Pieras-Lopez; M Diez; L Visa; R V Tocino; N Martínez Lago; M L Limón; M Gil; P Pimentel; M Mangas; M Granja; A M Carnicero; C Hernández Pérez; L G Gonzalez; P Jimenez-Fonseca; A Carmona-Bayonas
Journal:  ESMO Open       Date:  2022-06-14

5.  Response to first-line chemotherapy of docetaxel combined with platinum predicting the prognosis and subsequent treatment of patients with non-small cell lung cancer.

Authors:  Hongbing Liu; Ying Wu; Zhaofeng Wang; Yong Song
Journal:  Thorac Cancer       Date:  2014-07-03       Impact factor: 3.500

6.  High level of serum AMBP is associated with poor response to paclitaxel-capecitabine chemotherapy in advanced gastric cancer patients.

Authors:  Hao Huang; Yong Han; Jing Gao; Junnan Feng; Lei Zhu; Like Qu; Lin Shen; Chengchao Shou
Journal:  Med Oncol       Date:  2013-10-18       Impact factor: 3.064

7.  Current status and future of chemotherapy and biochemotherapy in gastroesophageal cancers.

Authors:  Florian Lordick; Dirk Jäger
Journal:  Gastrointest Cancer Res       Date:  2008-07

8.  Tumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas.

Authors:  G H Bain; E Collie-Duguid; G I Murray; F J Gilbert; A Denison; F McKiddie; T Ahearn; I Fleming; J Leeds; P Phull; K Park; S Nanthakumaran; K M Matula; H I Grabsch; P Tan; A Welch; L Schweiger; A Dahle-Smith; G Urquhart; M Finegan; R D Petty
Journal:  Br J Cancer       Date:  2014-02-25       Impact factor: 7.640

9.  Chemotherapy-induced neutropenia as a prognostic factor in advanced non-small-cell lung cancer: results from Japan Multinational Trial Organization LC00-03.

Authors:  Y Kishida; M Kawahara; S Teramukai; K Kubota; K Komuta; K Minato; T Mio; Y Fujita; T Yonei; K Nakano; M Tsuboi; K Shibata; S Atagi; T Kawaguchi; K Furuse; M Fukushima
Journal:  Br J Cancer       Date:  2009-09-29       Impact factor: 7.640

10.  REG Iα is a biomarker for predicting response to chemotherapy with S-1 plus cisplatin in patients with unresectable stage IV gastric cancer.

Authors:  A Sekikawa; H Fukui; X Zhang; T Maruo; T Tsumura; Y Okabe; T Wakasa; Y Osaki; T Chiba; T Tomita; T Oshima; J Watari; H Miwa
Journal:  Br J Cancer       Date:  2013-01-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.